Allergy Therapeutics: Market share gains, strong balance sheet, key 12 months ahead
AIM-listed Allergy Therapeutics has announced a period of strong financial and operational progress in interim results announced today, with market share gains in the European market and progress made towards breaking the $2bn US market.
CEO Manuel Llobet, CFO Nick Wykeman and Head of Comms Alan Bullimore outline the key points of the results in the short film below
Allergy Therapeutics Investors Video